Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council.

Abstract

Given the increased prevalence of type 2 diabetes worldwide, most patients are treated by their primary health care team (PHCT). PHCTs need guidance in choosing the best treatment regimen for patients, since the number of glucose-lowering agents (GLAs) is rapidly increasing, as is the amount of clinical data regarding these drugs. The American Diabetes Association/European Association for the Study of Diabetes Position Statement emphasizes the importance of personalized treatment and lists drug efficacy, risk of hypoglycemia, effect on weight, side effects, and cost as important parameters to consider when choosing GLAs. The suggested Israeli guidelines refocus earlier international recommendations from 2012 and 2015, based on emerging data from cardiovascular outcome trials as well as what we believe are important issues for patient care (i.e., durability, hypoglycemia risk, and weight gain).

• Authors: Ofri Mosenzon, Rena Pollack, Itamar Raz
• Journal: Diabetes care (Diabetes Care) Vol. 39 Suppl 2 Pg. S146-53 (Aug 2016) ISSN: 1935-5548 [Electronic] United States
• PMID: 27440827 (Publication Type: Journal Article, Practice Guideline)
• Copyright: © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Chemical References

• Hypoglycemic Agents

Topics

• Consensus
• Diabetes Mellitus, Type 2 (therapy)
• Female
• Humans
• Hypoglycemia (drug therapy)
• Hypoglycemic Agents (therapeutic use)
• Israel
• Practice Patterns, Physicians' (standards)
• Risk Reduction Behavior
• Societies, Medical (standards)
• United States